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Abstract  
As part of the World Cancer Research Fund/ American Institute for Cancer Research (WCRF-
AICR) Continuous Update project we performed a systematic review of prospective studies 
with data for both measured or predicted 25(OH)D concentration and kidney cancer risk. 
PubMed was searched from inception until 1st December 2014 using WCRF/AICR search 
criteria. 
The search identified 4 papers suitable for inclusion, reporting data from three prospective 
cohort studies, one nested case-control study and the Vitamin D Pooling Project of Rarer 
Cancers (8 nested case-control studies).  Summary effect sizes could not be computed due 
to incompatibility between studies.  All studies except the Pooling Project suggested a reduced 
risk of kidney cancer by 19-40% with higher or adequate vitamin D status, .   However, these 
estimates only reached statistical significance in one cohort (Copenhagen City Heart Study; 
CCHS, HR=0.75 (0.58 to 0.96)).  In the European Prospective Investigation into Cancer and 
Nutrition (EPIC) study, a significant reduction in risk by 18% was seen when using combined 
matched and non-matched controls OR=0.82 (0.68, 0.99), but not when using only matched 
controls (OR=0.81 (0.65, 1.00). Pooled (but not single cohort) data for predicted 25(OH)D from 
the Nurses’ Health Study (NHS) and Health Professionals Follow-up Study (HPFS) showed a 
statistically significant reduction in risk by 37% (HR=0.63 (0.44, 0.91)). 
There is no clear explanation for the inconsistency of results between studies, but reasons 
may include prevalence of smoking or other study population characteristics.  Methods for 
assessing circulating 25(OH)D levels and control for confounders including seasonality or 
hypertension do not seem explanatory. 
Keywords: Kidney Cancer, 25-hydroxyvitamin D, Systematic Review, Vitamin D, Nutrition  
Highlights  
 
 A systematic review of studies assessing 25(OH)D status and kidney cancer risk. 
 Four cohort or nested case-control studies and one Pooling Project were included. 
 Subject populations and smoking prevalence may explain between cohort differences. 
 An association between low 25(OH)D and kidney cancer risk could not be ruled out. 
 
 
  
1.0. Introduction  
 
 Kidney cancer is the 14th most frequent cancer worldwide1 with renal cell carcinoma the most 
common type.  Incidence rates increased until the middle of the 1990s and then stabilized, but 
recent estimates suggest that in some countries incidence rates are still increasing2. These 
trends might have been influenced by the use of new imaging tests and the changing 
prevalence of known risk factors including smoking and obesity3.       
The kidneys are the main tissue in the body responsible for hydroxylation of the circulating 
metabolite 25(OH)D to the active hormone 1,25-dihydroxyvitaminD (1,25(OH)2D). Most kidney 
cancers are of epithelial cell origin, and vitamin D has known beneficial anti-neoplastic 
properties in human epithelium4.  An inverse relationship has been found between 
occupational UVB exposure and renal cell carcinoma risk in men, which could be partly 
attributable to vitamin D status5.  In this systematic review we assessed the evidence from 
prospective studies on vitamin D status and kidney cancer risk, examining potential sources 
of heterogeneity between studies. 
  
2.0 Materials and Methods  
 
2.1. Search Strategy and Study Selection 
The search criteria and data extraction protocol used were those used in the WCRF/AICR  
Continuous Update Project (full protocol available at 
http://wcrf.org/sites/default/files/protocol_kidney_cancer.pdf).  Two reviewers independently 
selected the articles and extracted the data for the most highly adjusted model reported in 
each paper for renal cell carcinoma or kidney cancer.   Figure 1 illustrates the flow of articles 
through the selection process.  Four articles were relevant for inclusion containing data on 
three cohort studies (Copenhagen City Heart Study (CCHS)6, Nurses’ Health Study (NHS), 
Health Professionals Follow-Up Study (HPFS)7,  a nested case-control study (European 
Prospective Investigation into Cancer and Nutrition (EPIC) 8 and the Pooling Project of Rarer 
Cancers9, which included 8 nested case control studies (see Table 1 for details).   A report 
from the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC)10 was excluded 
as this cohort was already included in the Pooling Project9.  Circulating 25(OH)D was 
assessed from serum or plasma samples in all studies except the NHS and HPFS7 whereby 
25(OH)D was predicted using validated regression models that included major determinants 
of vitamin D status. 
 
FIGURE 1 ABOUT HERE  
 
2.2. Data analysis 
Study results were tabulated and shown in a forest plot. Summary estimates were not 
calculated due to the differences in the increment units and contrasts used in the studies.  
Contrasts chosen for inclusion in the forest plot were those closest to the well-established 
25(OH)D cut off points of >75nmol/L11 for optimal vitamin D status, compared to <25nmol/L 
(referent) for vitamin D deficiency. It must be borne in mind that these cut-off points have much 
debated in vitamin D literature.  For the Pooling Project9 (combined male and female estimate) 
the reference category was changed to <25nmol/L and the top two categories combined to 
produce a cut-off point of ≥75nmol/L, using the method described by Hamling et al. (2008)12.  
Two studies (CCHS, EPIC) presented the data for continuous increments of 25(OH)D and are 
also shown in the same forest plot.  To increase the comparability across study results, the 
HR of the CCHS data6 was recalculated to increments of doubling of 25(OH)D levels (originally 
expressed for reduction).   
 
  
3.0. Results  
 
Study characteristics are shown in Table 1. Overall, the studies on measured 25(OH)D 
concentration included 1390 kidney cancer or renal cell carcinoma cases. From these, 775 
kidney cancer cases are from the Vitamin D Pooling Project of Rarer Cancers, 55 cases are 
from the CCHS and 560 renal cell carcinoma cases are from EPIC. In the Vitamin D Pooling 
Project, the results for kidney cancer and renal cell carcinomas were similar. In all studies, 
25(OH)D was measured in only a single blood sample.  The NHS and HPFS cohorts 7 used 
predicted plasma 25(OH)D and included 408 cancer cases. 
 
TABLE 1 ABOUT HERE  
Figure 2 illustrates the forest plot of predicted or actual plasma vitamin D and kidney cancer.  
The Pooling Project 9 did not support an association of circulating 25(OH)D concentration with 
the risk of RCC, with an odds ratio of 1.18 (95% CI 0.63, 2.22) for the ≥75nmol/L as compared 
with <25 nmol/L(referent), and an odds ratio of 1.12 (0.79,1.59) for 25(OH)D concentration 
<37.5 nmol/L, as compared with 50-75 nmol/L (referent)(data not shown in the Figure).   For 
continuous data, in the CCHS6 lower plasma 25(OH)D was significantly related with a higher 
risk of kidney cancer6. The Hazard ratio for a 50% reduction in plasma 25(OH)D was 1.34 
(1.04,1.73). Equivalent data for a 50% increase in plasma 25(OH)D  was estimated as 0.75 
(0.58, 0.96).  In the EPIC study8 a doubling of 25(OH)D concentration was associated with a 
reduced odds of developing RCC of 0.82 (0.68, 0.99) in the combined control model (data not 
shown in the Figure 2), and 0.81 (0.65, 1.00) for the matched control model 8.   
For the studies on predicted vitamin D score, there was a non-statistically significant trend for 
a reduced risk of RCC by 40% in the NHS (women; HR=0.60 (0.35, 1.02) and by 34% in the 
HPFS (men; HR=0.66 (0.40, 1.09) for the top quintile of predicted 25(OH)D versus the lowest 
quintile (referent)7. Pooled results from the NHS and HPFS showed a statistically significant 
reduction in risk of RCC by 37% (HR=0.63 (0.44, 0.91) for equivalent quintiles 7(data not 
shown). In continuous analyses, the HR per 10 ng/mL (25nmol/L) of predicted 25 (OH)D  were 
0.61 (0.35, 1.04) in the HPFS cohort, 0.70(0.45, 1.07) in the NHS cohort7 and 0.66 (0.47 to 
0.92) (ptrend=0.009) for both combined.    
 
FIGURE 2 ABOUT HERE 
 
Sub-analyses undertaken in the Pooling Project showed that women with the highest 
25(OH)D (i.e. 75nmol/L or over) have a significantly reduced risk of all kidney cancer than 
women with 25(OH)D of 50-74nmol/L9.  However, this effect was not statistically significant 
when <25nmol/L (referent) was compared with ≥75nmol/L (Table 1). However, there was no 
effect modification by sex in the EPIC study8, and in the cohorts with predicted circulating 
25(OH)D scores (NHS and HPFS), similar inverse associations were observed in men and 
women. 
  
4.0. Discussion  
This systematic review showed inconsistent evidence as to whether kidney cancer risk is 
related to vitamin D status.   No association was observed in the Pooling Project of Rarer 
Cancers9. A significant inverse association with kidney cancer was observed in the CCHS 6 
(only 55 kidney cancer cases) and in EPIC,  lower risk of renal cell carcinoma was observed 
with a doubling of circulating 25(OH)D concentration, but only when combined controls rather 
than matched controls were used. Also, when combined, the two studies using predicted 
25(OH)D scores (NHS and HPFS) showed significant inverse association with kidney cancer 
risk. However, results were not statistically significant for the two cohorts separately. 
The reasons for the different results between cohorts are unclear. In EPIC 8 25(OH)D3 was 
determined by liquid chromatography coupled with tandem mass spectrometry (LC-MS). Both 
the Pooling Project13 and the CCHS6 used DiaSorin Liaison TOTAL 25(OH)D 
chemiluminescent immunoassay for measuring both 25(OH)D2 and 25(OH)D3.  It is known 
that radioimmunoassay (RIA) and chemiluminescent immunoassay (CLIA) measurements of 
25(OH)D (e.g.) differ from chemical based measurements (e.g. High Performance Liquid 
Chromatography (HPLC) or LC-MS) of 25(OH)D by up to 18%14. Two study results (CCHS 6 
and the Pooling Project9) which used the same measurement technique (DiaSorin Liaison 
25(OH)D TOTAL) gave different results,  which measures both 25-hydroxyvitamin D3 
(25(OH)D3) and 25-hydroxyvitamin D2 (25(OH)D2).  The EPIC study8 was the only study to 
use LC-MS to assess vitamin D status, using only the 25(OH)D3 measurement in the analysis 
as 25(OH)D2 was not detectable in most samples.  It is unlikely that the inclusion of 25(OH)D2 
in some of the analyses, but not others explains any difference in results between-studies as 
25(OH)D2 is usually present in much lower concentrations than 25(OH)D3 in human blood, 
and most likely has lower biological efficacy15.  Some differences between study results may 
be due to differences in study follow up times. For instance, the CCHS cohort had a relatively 
long follow-up (28 years) and showed a statistically significant result, as did HPFS and NHS 
studies (22 years), which showed a significant reduction in risk with increasing 25(OH)D 
concentration (pooled data for both cohorts only). A longer follow up time may render the 
baseline 25(OH)D measurement less representative of the persons vitamin D status closer to 
the time of diagnosis.  This must be borne in mind when interpreting the results for the studies 
with longer follow-up times.  
All studies controlled for season of blood collection using either residual adjustment6, 9 or 
trigonometric functions8 in the models, and also all studies controlled for main potential 
confounders including BMI and smoking. The Pooling project9 adjusted for hypertension and 
in a sub analysis in EPIC8, adjustment for hypertension did not modify the results. The CCHS6, 
with a small number of cases, did not adjust for hypertension. 
The proportion of current and former smokers was highest in the Pooling Project, with 37% of 
kidney cancer cases coming from participants in the ATBC cohort9.  Smokers may have an 
increased risk of kidney cancer but also have a lower level of circulating 25(OH)D16. In the 
ATBC cohort, median circulating 25(OH) levels (31.6nmol/L in the controls) were lower than 
the average in the overall study populations.  After exclusion of the ATBC participants from 
the Vitamin D Pooling project analyses, a U shape relationship was suggested with odds ratios 
of 0.75 (95% CI: 0.40-1.41) for <25 nmol/L and 0.57 (95% CI:0.27, 1.17) for  ≥100 nmol/L  
compared to 50-75 nmol/L. In the Pooling Project, high 25(OH)D concentrations (≥75 nmol/L) 
were associated with a non-statistically significant increased risk of kidney cancer for males 
(OR : 1.52, 95% CI: 0.95, 2.41) compared with 50-<75nmol/L (referent).  These results 
remained similar when the cohort subjects from the ATBC were excluded. In contrast, among 
females, high concentrations of 25(OH)D were associated with a statistically significant 
decreased risk of kidney cancer (OR: 0.31, 95% CI: 0.12, 0.85) compared with 50-<75mol/L, 
although, there was no statistical evidence of a sex–25(OH)D interaction (P : 0.42). Of note, 
in the EPIC study the stratified odds ratios for a doubling in circulating 25(OH)D values were 
0.79 (95% CI: 0.60-1.05) in never smokers, 0.70 (95% CI: 0.50-0.98) in former smokers but 
0.93 (0.69-1.26) in current smokers, suggesting a weaker association in current smokers. In 
other stratified analyses within the EPIC study, strongest inverse associations with circulating 
25(OH)D levels were observed among the obese participants  but there was no significant 
interaction with BMI, smoking, sex or other factors investigated.  
 
5.0. Conclusion 
There is no clear explanation for the inconsistent results seen in this review, but differences 
in study populations and specifically the prevalence of smoking might partially explain it. For 
instance, EPIC and the CCHS were in European populations, whereas the Pooling Project 
included populations from Asia, Europe and USA.  This review is limited by the small number 
of studies in the review and the possibility of publication bias. Overall, the existing evidence 
does not rule out a possible beneficial effect of adequate vitamin D status against kidney 
cancer development.  
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 Legends for Tables and Figures 
 
Table 1: Studies on circulating 25(OH)D concentration and kidney cancer incidence 
identified in systematic review  
 
Figure 1: Flow chart of the search for articles on vitamin D status and kidney cancer- 
PubMed inception to 1st December 2014 
 
Figure 2: Association between circulating 25(OH)D and kidney cancer.   
Note for figure 2: *Reference category changed so risk is for a 50% increase in 25(OH)D 
rather than a 50% decrease **Reference category was changed to <25nmol/L and the top 
two categories pooled to produce a cut-off point of =>75nmol/L ***ATBC; CLUE; CPS-II; 
MEC; NYU-WHS; PLCO; SMHS/SWHS **** Matched control data displayed here; combined 
control data gave a statistically significant effect (OR=0.82 (0.68, 0.99)).   
Table 1 
Author, 
year 
Country, 
design 
Study 
name 
25(OH)D 
Measure, 
ratio± 
Method 
25(OH)D 
Form of 
25(OH)D  
Cases Years 
follow 
up 
Type Sex Ratio LCI UCI Contrast (High 
vs. Low) 
Controls 
matched to 
cases by: 
Data 
adjustments 
Afzal et al. 
20136 
Denmark, 
Prospective 
cohort 
CCHS Plasma 
25(OH)D, 
HR 
DiaSorin 
Liaison 
TOTAL 
CLIA 
D2/D3 55 28 KC M/
W 
0.75 0.58 0.96 50% reduction in 
25(OH)D no vs. 
yes (referent) 
- Age, sex, 
smoking, BMI, 
alcohol, leisure 
time and work-
related 
physical 
activity, 
education. 
Gallicchio 
et al. 20149 
Various, 
Nested Case 
control 
Pooling 
Project of 
Rarer 
Cancers d 
Serum and 
Plasma 
25(OH)D, 
OR 
DiaSorin 
Liaison 
TOTAL 
CLIA 
D2/D3 775 2.2-
10.9  
RCC M/
W 
1.18 0.63 2.22 ≥75 nmol/L vs. 
<25nmol/L 
(referent) 
Age, sex, race, 
and season 
Education, 
BMI, smoking 
status, 
hypertension, 
diabetes, 
height, alcohol  
KC 
 
M 1.46 0.78 2.72 
W 0.47 0.12 1.90 
Joh et al. 
20137 
USA,  
Prospective 
cohort 
NHS  Predicted 
25(OH)D e 
HR 
Predicted 
 
- 201 22 RCC 
 
W 0.60 0.35 1.02 80 nmol/L vs.56 
nmol/L (referent) 
 
- Age, BMI, 
smoking 
status, history 
of 
hypertension 
and diabetes, 
and parity (F) 
0.70 0.45 1.07 Per 10ng/mL* 
increment 
 
HPFS Predicted 
25(OH)D e 
HR 
Predicted - 207 22 RCC M 0.66 0.40 1.09 70 nmol/L vs. 50 
nmol/L (referent) 
 
0.61 0.35 1.04 Per 10ng/mLb 
increment 
 
Muller et al. 
20148 
Europe, 
Nested Case 
Control 
EPIC Plasma 
25(OH)D, 
OR 
LC-MS D3  
(D2 
undetect
able) 
560 6.7  RCC M/
W 
0.81 0.65 1.00 Doubling in 
25(OH)D yes vs. 
no (referent) 
Country, sex, 
date of blood 
collection, birth 
date 
Alcohol intake, 
BMI, smoking  
a: quartile dose average of summer and winter quartile values, b: 10ng/mL=25nmol/L, c : Trial included male smokers only who smoked 5+ cigarettes per day, d: Pooling Project: Alpha-Tocopherol, Beta-Carotene 
Cancer Prevention Study (ATBC); the Cancer Prevention Study II Nutrition Cohort (CPS-II); CLUE; the Multiethnic Cohort Study (MEC); the New York University Women’s Health Study (NYU-WHS); the Prostate, 
Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO); the Shanghai Men’s Health Study (SMHS); Shanghai Women’s Health Study (SWHS),  e: Predicted 25(OH)D based on race, UVB radiation at place of 
residence, leisure physical activity, BMI, dietary vitamin D, supplemental vitamin D, alcohol intake and use of postmenopausal hormone treatments (NHS only).   
Note: ±OR=odds ratio, HR=hazard ratio LCI=lower confidence interval (95%), UCI=upper confidence interval (95%)  EPIC=European Prospective Investigation into Cancer; NHS=Nurses Health Study, HPFS= 
Health Professionals Follow-up Study, CCHS=Copenhagen City Heart Study.  KC=mixed kidney cancer type, RCC=renal cell carcinoma
Figure 1 
 
 
 
 
 
 
  
 
Figure 2 
  
Measured
Gallicchio
Afzal
Muller
Predicted
Joh
Joh
Author
2010
2013
2014
2013
2013
Year
M/W
M/W
M/W
W
M
Sex
1.18 (0.63, 2.22)
0.75 (0.58, 0.96)
0.81 (0.65, 1.00)
0.60 (0.35, 1.02)
0.66 (0.40, 1.09)
Estimate (95% CI)
Various***
CCHS
EPIC
NHS
HPFS
Cohort
>=75nmol/L vs. <25nmol/L (referent)**
50% increase in 25(OH)D*
Doubling of 25(OH)D****
Quintile 5 (median 80nmol/L) vs. Quintile 1 (median 58nmol/L) (referent)
Quintile 5 (median 70nmol/L) vs. Quintile 1 (median 50nmol/L) (referent)
Contrast
  
1.5 1.5 2
